Mar 27, 2012
12:43 pm EDT
The Rockefeller Foundation was originally set up in 1904 as the General Education Fund. The RF was later formed in 1910 and issued a charter on May 14, 1913 with the help of Rockefeller millions. Subsequently, the foundation placed it’s own “nominees” in federal health agencies and set the stage for the “reeducation” of the public. A compilation of magazine advertising reveals that as far back as 1948, larger American drug companies spent a total sum of $1,104,224,374 for advertising. Of this sum, Rockefeller-Morgan interests (which went entirely to Rockefeller after Morgan’s death) controlled about 80%.  See also AMA.
IG Farben & Auschwitz
Auschwitz was the largest mass extermination factory in human history. However, few people are aware that Auschwitz was a 100% subsidiary of IG Farben. On April 14, 1941, in Ludwigshafen, Otto Armbrust, the IG Farben board member responsible for the Auschwitz project, stated to board colleagues:
“our new friendship with the SS is a blessing. We have determined all measures integrating the concentration camps to benefit our company.”
Thousands of prisoners died during human experiments, drug and vaccine testing. Before longtime Bayer employee and SS Auschwitz doctor Helmut Vetter was executed for administering fatal infections, he wrote to his bosses at Bayer headquarters:
“I have thrown myself into my work wholeheartedly. Especially as I have the opportunity to test our new preparations. I feel like I am in paradise.”
After WWII, IG Farben attempted to shake its abominable image through corporate restructuring and renaming. So great has been their success that the public has no idea that it many of the men responsible for such atrocities, were able to carry on their work even after the collapse of the Nazi regime. Namely a medical paradigm that relies almost exclusively highly toxic drugs. Such men were in control of the large chemical and pharmaceutical companies, both well before and after Hitler. The Nuremberg Tribunal convicted 24 IG Farben board members and executives on the basis of mass murder, slavery and other crimes. Incredibly, most of them had been released by 1951 and continued to consult with German corporations. The Nuremberg Tribunal dissolved IG Farben into Bayer, Hoechst, and BASF, each company 20 times as large as IG Farben in 1944. For almost three decades after WWII, BASF, Bayer and Hoechst (Aventis) filled their highest position, chairman of the board, with former members of the Nazi regime. Bayer has been sued by survivors of medical experiments such as Eva Kor who, along with her sister, survived experiments at the hands of Dr. Josef Mengele.
Drug companies have new top salesmen: doctors. According to a mid-July 2005 report by the Wall Street Journal, hiring a doctor to speak about drug therapies to other doctors has proven to be a “highly effective” way for the pharmaceutical industry to market its drugs.
“An internal study done by Merck & Co. several years ago calculated the “return on investment” from doctor-led discussion groups was almost double the return on meetings led by the company’s own sales force. According to the document, doctors who attended a lecture by another doctor wrote an additional $623.55 worth of prescriptions for the painkiller Vioxx over a 12-month period compared with doctors who didn’t attend. Doctors who participated in the more intimate discussions wrote an additional $717.53 worth of prescriptions for Vioxx, which Merck pulled from the market last year over concerns about cardiovascular side effects. That compared to an increase of only $165.87 in Vioxx prescriptions by doctors who attended a meeting with a salesperson.”
In 1996, researcher Sheldon Krimsky of Tufts University studied nearly 800 scientific papers in prominent biology and medical journals. In one third of all cases, the author had financial interests in the company sponsoring the research. This information was not disclosed to readers in most cases. In a 1996 Stanford University study by Mildred Cho, a senior research scholar at the Center for Biomedical Ethics; found that 98% of university studies funded by drug companies reported new therapies to be more effective than standard ones. By comparison, only 79% of non-industry financed studies found new drugs to be more effective
Posted by Thomasmkelly